ITVISMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene. Under the CDSCO Named Patient Program, Indian patients can legally import breast cancer drugs that are FDA-approved in other countries but not commercially marketed in India.
| Brand Name: | ITVISMA |
| Generic Name: | onasemnogene abeparvovec-brve injection |
| Strength: | Each single-dose vial contains 1.2 × 1014 vg of onasemnogene abeparvovec in 3 mL of suspension. ITVISMA has a nominal concentration of 4 ×1013 vg/mL, and each vial contains an extractable volume of not less than 3 mL. |
| Manufacturer: | Novartis Gene Therapies |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
Get access ITVISMA for spinal muscular atrophy (SMA) Treatment through Named-Patient Import in India
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to ITVISMA (onasemnogene abeparvovec-brve) injection for personal use. For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
